TY - JOUR
T1 - BCL-2 inhibition in follicular lymphoma
T2 - can we tip the scales?
AU - Fowler, Nathan
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology
PY - 2020/12/3
Y1 - 2020/12/3
N2 - In this issue of Blood, Zinzani et al1 report the results of the open-label phase 2 CONTRALTO study, which evaluated the additional benefit of adding the BCL-2 inhibitor, venetoclax (VEN), to common treatment backbones, such as rituximab and bendamustine plus rituximab, in patients with relapsed/ refractory follicular lymphoma (FL).
AB - In this issue of Blood, Zinzani et al1 report the results of the open-label phase 2 CONTRALTO study, which evaluated the additional benefit of adding the BCL-2 inhibitor, venetoclax (VEN), to common treatment backbones, such as rituximab and bendamustine plus rituximab, in patients with relapsed/ refractory follicular lymphoma (FL).
UR - http://www.scopus.com/inward/record.url?scp=85097121260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097121260&partnerID=8YFLogxK
U2 - 10.1182/BLOOD.2020008194
DO - 10.1182/BLOOD.2020008194
M3 - Article
C2 - 33270856
AN - SCOPUS:85097121260
SN - 0006-4971
VL - 136
SP - 2598
EP - 2600
JO - Blood
JF - Blood
IS - 23
ER -